中国经济网北京1月28日讯 光环新网(300383.SZ)26日发布2025年度业绩预告。经财务部门初步测 算，光环新网预计2025年年度实现归属于母公司所有者的净利润为亏损73000万元至78000万元，去年 同期为盈利38144.48万元。公司预计2025年年度实现归属于母公司所有者的扣除非经常性损益后的净 利润为亏损77000万元至82000万元，去年同期为盈利34638.05万元。公司预计2025年年度营收为71.7 亿元至72.2亿元。 | 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司股 东的净利润 | 亏损:73,000 万元-78,000 万元 | 盈利:38,144.48万元 | | 扣除非经常性损益 后的净利润 | 亏损:77,000万元-82,000万元 | 盈利:34,638.05 万元 | | 营业收入 | 717,000.00 万元-722,000.00 万元 | 728, 121. 03 万元 | | 扣除后营业收入 | 717,000.00 万元-722,000.00 万元 | 728, 121. 03 万元 | 本次计提商誉减 ...

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 18.29 CNY [5][9]. Core Insights - The company is expected to turn from profit to loss in 2025, primarily due to significant goodwill impairment related to acquisitions such as Zhongjin Yunwang. Despite short-term pressure on IDC and cloud computing businesses, cabinet deployment is accelerating, and performance is expected to recover rapidly in 2026 [2][9]. - The forecasted revenue for 2025 is between 7.17 billion to 7.22 billion CNY, representing a year-on-year decline of 0.84% to 1.52%. The net profit attributable to shareholders is projected to be a loss of 749 million CNY, compared to a profit of 346 million CNY in the previous year [9]. Financial Summary - Total revenue for 2023 is 7,855 million CNY, with a projected decrease to 7,208 million CNY in 2025, followed by a slight recovery to 7,384 million CNY in 2026 and 7,996 million CNY in 2027 [4][10]. - The net profit attributable to shareholders is forecasted to decline from 388 million CNY in 2023 to a loss of 749 million CNY in 2025, with a recovery to 328 million CNY in 2026 and 450 million CNY in 2027 [4][10]. - The company’s net asset return rate is expected to drop to -6.3% in 2025, with a recovery to 2.7% in 2026 and 3.5% in 2027 [4][10]. Business Performance - The company is facing challenges in its IDC business due to increased competition and customer retention issues, with a significant number of new cabinets deployed (over 26,000) leading to increased depreciation costs [9]. - The cloud computing segment is also under pressure due to the expiration of specific operational assets and adjustments in customer structure, leading to a projected revenue decrease of approximately 106 million CNY in 2025 [9]. - Despite short-term challenges, the company has significantly increased its cabinet deployment, with over 82,000 cabinets in operation by the end of 2025, and plans for over 230,000 cabinets nationwide, positioning itself to benefit from future demand driven by AI [9].

Group 1 - The company, Weidi Co., Ltd., announced a significant decrease in its expected net profit for the year 2025, projecting a range of 2.47 million to 3.70 million yuan, which represents a decline of 26.81% to 51.14% compared to the previous year's profit of 5.0555 million yuan [2] - The expected net profit after deducting non-recurring gains and losses is projected to be between 2.08 million and 3.10 million yuan, down 25.35% to 49.91% from 4.1528 million yuan in the previous year [2] - The main reasons for the profit reduction include lower gross margins from new passenger car electronic products and optical injection molded parts, a decrease in bank interest income due to reduced deposit principal and declining interest rates, and increased expenses from the addition of a new subsidiary in the consolidated financial statements [2] Group 2 - The announcement also included a significant risk warning regarding the company's subsidiary, Anhui Alpha Silicon New Energy Common Technology Research Institute Co., Ltd. (Alpha Silicon), which was acquired at the end of 2024 and has generated goodwill of 25.482 million yuan [3] - Preliminary assessments indicate that Alpha Silicon's operating performance is below expectations, and the financial data is still undergoing special evaluation and audit procedures [3] - If further impairment of goodwill is required after the evaluation and audit, it could result in a negative net profit for the company, which, combined with insufficient annual revenue of less than 300 million yuan, may lead to a delisting risk warning for the company's stock after the 2025 annual report is disclosed [3]

Core Viewpoint - The stock price of Gaoshi Medical (02407) has experienced fluctuations following its removal from the Hong Kong Stock Connect list, with a significant increase in the first half of the year, but a subsequent decline of nearly 20% since December 22, raising questions about its upcoming performance in the 2025 annual report [1][2][7]. Group 1: Stock Performance - Gaoshi Medical's stock price rose by 65.50% from May to September last year, despite being removed from the Hong Kong Stock Connect list in March [1]. - Following a peak, the stock entered a three-month period of consolidation before declining after December [1]. - The stock has seen a cumulative decline of nearly 20% since December 22, effectively reversing all gains made since the mid-year report [1]. Group 2: Hong Kong Stock Connect Impact - On March 10, the adjustment of the Hong Kong Stock Connect list led to an average stock price drop of 14.24% for excluded stocks, with Gaoshi Medical being one of the affected companies [1]. - Despite the stock's removal, the proportion of shares held by Hong Kong Stock Connect investors decreased only slightly from 6.85% to 3.85% over ten months, indicating limited selling pressure [2]. Group 3: Trading Volume and Liquidity - Post-removal, the trading volume of Gaoshi Medical's shares significantly decreased, with a drop of 84.39% in monthly trading volume from February to April compared to the previous period [4]. - By December, the monthly trading volume had further declined to just 97.35 million shares [4]. Group 4: Financial Performance - In 2024, Gaoshi Medical reported revenues of 1.428 billion yuan, a year-on-year increase of 1.6%, but a 4.1% decrease in gross profit to 663 million yuan, with net profit down 46.75% to 92.39 million yuan [7]. - The decline in profitability was attributed to factors such as exchange rate fluctuations and the implementation of national procurement policies for artificial crystals, alongside goodwill impairment totaling 23.26 million yuan [7]. Group 5: Business Strategy and Future Outlook - Gaoshi Medical is attempting to adjust its business structure by increasing the proportion of self-owned products, although the revenue share from distribution products increased to 68.55% in 2024 [8]. - The company reported a significant improvement in its financials for the first half of 2025, with revenues of 653 million yuan, a 1.7% increase, and a net profit of 35.9 million yuan, up 33.5% [8]. - Analysts project revenue growth for 2025-2027, with expected revenues of 1.564 billion, 1.715 billion, and 1.875 billion yuan, and net profits of 135 million, 180 million, and 214 million yuan respectively [9].

中国中药(00570)跌超4%，截至发稿，跌4.57%，报2.09港元，成交额1129.92万港元。 本期由盈转亏主要原因为：中药配方颗粒业务受集采业务占比提高、市场竞争加剧等影响，收入规模及 盈利能力下降;及本期商誉减值、无形资产减值及信用减值增加;及经调整溢利净额为扣除以下各项影响 后的溢利净额：商誉及相关资产组减值;及部分附属公司补缴税款。 消息面上，中国中药公布，预期集团截至2025年12月31日止年度由盈转亏，亏损净额区间预计约为人民 币3.50亿元至5亿元，上年同期溢利净额约为人民币2077万元；及本期经调整溢利净额同比下降45%至 55%，上年同期约为人民币6.355亿元。 ...

Core Viewpoint - The company anticipates a significant increase in net profit for the year 2025, projecting a rise of over 50% compared to the previous year, driven by various factors including fair value changes in investments [2][3]. Financial Performance Forecast - The company expects to achieve a net profit attributable to shareholders of between 90 million and 115 million yuan for 2025, representing an increase of 68.09 million to 93.09 million yuan compared to the previous year, which translates to a year-on-year growth of 310.86% to 424.99% [2][3]. - The projected net profit, excluding non-recurring gains and losses, is estimated to be between 40.83 million and 55 million yuan, with an increase of 0 to 14.17 million yuan compared to the previous year, indicating a growth rate of 0% to 34.70% [2][3]. Previous Year’s Financial Performance - In the previous year, the total profit was 47.30 million yuan, with a net profit attributable to shareholders of 21.91 million yuan. The net profit after excluding non-recurring gains and losses was 40.83 million yuan [5]. Reasons for Performance Change - The increase in net profit for 2025 is attributed to the fair value measurement of the investment in Anbang Guard Group Co., Ltd., which resulted in a fair value change gain of 32.54 million yuan, contributing an additional 24.41 million yuan to the current net profit. In contrast, the previous year recorded a fair value change loss of 53.06 million yuan, which reduced the net profit by 39.80 million yuan [7]. - The company has identified potential impairment risks related to goodwill from the acquisition of Shanghai Cailin Property Management Co., Ltd. and Zhejiang Zhongda Puhui Property Co., Ltd., and plans to recognize a goodwill impairment provision of approximately 45 million yuan [7].

证券代码：603858 证券简称：步长制药 公告编号：2026-012 山东步长制药股份有限公司 关于为公司控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 担保对象及基本情况 （一）担保的基本情况 山东步长制药股份有限公司（以下简称 "公司"）于2026年1月26日与北京银行股份有限公司北京经济技 术开发区分行（以下简称 "北京银行北京经济技术开发区分行"）签订了《最高额保证合同》，为公司 控股子公司北京博源润步医药研发有限公司（以下简称 "博源润步"）与北京银行北京经济技术开发区 分行签订的《综合授信合同》提供3,000万元连带责任保证。 （二）内部决策程序 公司于2025年4月25日召开第五届董事会第二十次（年度）会议，于2025年6月26日召开2024年年度股东 会，审议通过了《关于审议公司及控股子公司2025年度预计新增融资额度及担保额度的议案》，同意 2025年度公司及控股子公司向金融机构申请授信总额不超过人民币69.20亿元的综合融资额度。上述融 资事项如需采用保证或抵 ...

格隆汇1月27日丨东星医疗(301290.SZ)公布，预计2025年归属于上市公司股东的净利润-4,500万元 ～-3,200万元，扣除非经常性损益后的净利润-7,200万元～-5,100万元。1、报告期内，受市场竞争加剧 和客户需求放缓的影响，公司吻合器零部件、医疗设备相关业务收入有所下降，致使主营业务整体毛利 较上年同期有所减少；2、根据《企业会计准则第 8 号——资产减值》及相关会计政策规定，基于谨慎 性原则，结合对全资子公司江苏孜航精密五金有限公司 2025 年度及未来经营业绩、盈利能力的分析， 公司对截至 2025 年 12 月 31 日的资产组进行了减值测试。经初步测算，公司预计2025 年度计提商誉减 值准备金额约为 9,790.94 万元，计提无形资产减值准备的金额约为562.92 万元，减值准备金额合计约为 10,353.86 万元。本次业绩预告情况已考虑拟计提资产减值准备对公司净利润的影响。截至本公告披露 日，上述资产减值测试工作尚在进行中，最终资产减值准备计提金额将由公司聘请的具备证券期货从业 资格的评估机构及审计机构进行评估和审计后确定。 ...

格隆汇1月27日丨拓尔思(300229.SZ)公布，预计2025年归属于上市公司股东的净利润-31,000万元 ～-25,000万元，扣除非经常性损益后的净利润-36,500万元～-31,400万元。报告期内，公司子公司拓尔 思天行网安信息技术有限责任公司（以下简称"天行网安"）所处网络安全行业市场恢复情况不及预期导 致业绩再次出现亏损。基于天行网安 2025 年营业收入及收入增长预计情况，结合相关行业报告进行谨 慎预测，公司 2025 年度拟对其计提商誉减值准备。根据《会计监管风险提示第 8 号——商誉减值》及 《企业会计准则第8 号——资产减值》的相关要求，拟计提商誉减值准备金额范围在 16,000 万 元-14,000 万元之间。在本次计提商誉减值准备之前，公司商誉账面价值合计 38,653 万元，本次计提商 誉减值准备后，商誉账面价值为 22,653 万元-24,653 万元之间。最终商誉减值准备计提数据将由公司聘 请的具有从事证券、期货相关业务资格的评估机构及审计机构进行评估和审计后确定。 ...

董事会认为：集团本期由盈转亏主要原因为：中药配方颗粒业务受集采业务占比提高、市场竞争加剧等 影响，收入规模及盈利能力下降;及本期商誉减值、无形资产减值及信用减值增加;及经调整溢利净额为 扣除以下各项影响后的溢利净额：商誉及相关资产组减值;及部分附属公司补缴税款。 中国中药(00570)发布公告，预期集团截至2025年12月31日止年度由盈转亏，亏损净额区间预计约为人 民币3.50亿元至5亿元，上年同期溢利净额约为人民币2077万元;及本期经调整溢利净额同比下降45%至 55%，上年同期约为人民币6.355亿元。 ...